Globel community doubts on China scientific research jagran.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jagran.com Daily Mail and Mail on Sunday newspapers.
Share:
While only in business for less than two years, Rida Zayn has quickly turned her cosmetics business into the top brand in Pakistan. This has helped to make her one of the youngest and most successful entrepreneurs in the country, a remarkable accomplishment considering how long the company has been in operation.
Rida Zayn Cosmetics began in 2019, and quickly became a hit with women across the country. While providing a quality product, she also ensured that she was respectful of the culture and practices of the country, which is seen in the beauty, elegance, and simplicity of her cosmetics line.
Dr. Dong Zhao Announced as Deputy Editor of JACC: Asia
China-based physician scientist among prestigious representatives of cardiovascular health to serve on journal’s editorial board
Feb 08, 2021
WASHINGTON (Feb 08, 2021) -
Dong Zhao, MD, PhD, has been named a deputy editor of
JACC: Asia, the American College of Cardiology’s newest journal, which will feature original articles, cutting-edge technology manuscripts and clinical practice guidelines centered on Asian populations and by Asian authors.
A distinguished clinical epidemiologist, Zhao is currently a professor of preventive cardiology at the Beijing Institute of Heart, Lung and Blood Vessel Diseases (BIHLBD) at Beijing Anzhen Hospital, Capital Medical University. She is the former deputy director of BIHLBD. Zhao is also a member of several writing committees on China and international guidelines focused on preventive cardiology, dyslipidemia management and hypertension management.
Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ I-Mab (the Company ) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial (NCT04600817) of TJ107 (efineptakin alpha), a novel long-acting recombinant human interleukin-7 (rhIL-7), in patients with glioblastoma multiforme (GBM) in China.
The phase 2 trial is a randomized, single-blind, placebo-controlled study to evaluate the efficacy and safety of TJ107 in lymphopenic patients with newly diagnosed GBM who have been treated with standard concurrent chemoradiotherapy. The study s goal is to determine the proportion of patients with an increase in the absolute lymphocyte counts and associated clinical response after the administration of the first TJ107 dose.
Experts from Capital Medical University, Beijing, developed a simple, low-cost, and efficient custom transcription activator-like effector (TALE) gene synthesis method using a twin primer assembly. The method is published in BioTechniques.